Glutamine in Preventing Peripheral Neuropathy in Patients With Multiple Myeloma Receiving Bortezomib

Phase 2 Terminated 9 enrolled Beth Faiman National Cancer Institute (NCI) · collab

RandomizedParallel-groupDouble-blindPrevention

Summary

This randomized phase II trial studies glutamine in preventing peripheral neuropathy in patients with multiple myeloma who are receiving bortezomib. Glutamine may help prevent peripheral neuropathy in patients receiving chemotherapy

Timeline

Start: 2013-02
Primary completion: 2013-11
Completion: 2013-11

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Glutamine	Other / unclassified	15 g	Oral

Glutamine in Preventing Peripheral Neuropathy in Patients With Multiple Myeloma Receiving Bortezomib

Summary

Timeline

Drugs

Indications